Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2044 Target Snapshot

4-aminobutyrate aminotransferase, mitochondrial · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
110Compounds
41Assays
0Approved Drugs
59.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

4-aminobutyrate aminotransferase, mitochondrial shows approved-linked disease relevance led by complex partial epilepsy. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P80404. Start with complex partial epilepsy, then reuse UniProt P80404 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with complex partial epilepsy, then reuse UniProt P80404 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
complex partial epilepsy

4-aminobutyrate aminotransferase, mitochondrial shows approved-linked disease relevance led by complex partial epilepsy. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with complex partial epilepsy because it currently carries approved-linked support. Linked drugs include VIGABATRIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 4-aminobutyrate aminotransferase, mitochondrial as ChEMBL target CHEMBL2044, mapped to UniProt P80404. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
4-aminobutyrate aminotransferase, mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2044
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P80404
4-aminobutyrate aminotransferase, mitochondrial
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 4-aminobutyrate aminotransferase, mitochondrial is the right protein anchor across sources, using UniProt P80404 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why complex partial epilepsy is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name4-aminobutyrate aminotransferase, mitochondrial
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP80404
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label4-aminobutyrate aminotransferase, mitochondrial
UniProt AccessionP80404
Component TypeProtein
Sequence Length500 aa

4-aminobutyrate aminotransferase, mitochondrial

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 4-aminobutyrate aminotransferase, mitochondrial, mapped to UniProt P80404. Sequence length is 500 aa.

Mapped IDP80404
Review name4-aminobutyrate aminotransferase, mitochondrial
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

4-aminobutyrate aminotransferase, mitochondrial shows approved-linked disease relevance led by complex partial epilepsy. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
complex partial epilepsy
1 linked drug · 1 direct · 1 efficacy
Linked drugVIGABATRIN
Approved-linked Approved
developmental and epileptic encephalopathy
1 linked drug · 1 direct · 1 efficacy
Linked drugVIGABATRIN
Approved-linked Approved
epilepsy
1 linked drug · 1 direct · 1 efficacy
Linked drugVIGABATRIN
Approved-linked Approved
Epileptic spasm
1 linked drug · 1 direct · 1 efficacy
Linked drugVIGABATRIN
Approved-linked Approved
partial epilepsy
1 linked drug · 1 direct · 1 efficacy
Linked drugVIGABATRIN
Approved-linked Approved
West syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugVIGABATRIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with complex partial epilepsy because it currently carries approved-linked support. Linked drugs include VIGABATRIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecomplex partial epilepsy
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5029.0
KI30.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4580220 6.65 Ki 222.4 Preclinical
CHEMBL3589752 5.68 Ki 2100.0 Preclinical
CHEMBL4165749 5.59 Ki 2560.0 Preclinical
CHEMBL4522930 5.58 Ki 2622.51 Preclinical
CHEMBL378577 5.26 IC50 5480.0 Preclinical
CHEMBL353363 5.05 Ki 9000.0 Preclinical
CHEMBL4746439 5.01 IC50 9690.0 Preclinical
CHEMBL4740703 4.91 IC50 12230.0 Preclinical
CHEMBL202519 4.81 IC50 15400.0 Preclinical
CHEMBL378361 4.81 IC50 15500.0 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
3
5.5
0
6.0
1
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

41
Total Assays
35
Tested Compounds
1
Assay Types
Binding — 41 assays, 35 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 41 35 5.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine